Michael Karin

USPTO Granted Patents = 54 (Patent Applications = 8)

Average Co-Inventor Count = 2.6

ph-index = 12

Forward Citations = 567(Granted Patents)

Forward Citations (Not Self Cited) = 526(Dec 10, 2025)

Inventors with similar research interests:

Location History:

San Francisco, CA (US) (1985)
Los Angeles, CA (US) (1986)
San Diego, CA (US) (1996 - 2008)
La Jolla, CA (US) (2003 - 2024)

Company Filing History:

48 out of 15,475

University of California

Charterhouse Therapeutics Ltd.

patents

6. 1 out of 601

Baylor College of Medicine

patents

7. 1 out of 94

The Burnham Institute

La Jolla Cancer Research Foundation

patents

10. 2 out of 832,843

Other

patents

where one patent can have more than one assignee

Years Active: 1985-2025

Loading Chart...

Areas of Expertise:

Combination Therapy

Cancer Treatment

Anti-CXCR5 Antibodies

NLRP3 Inflammasome

Hepatocyte Regeneration

Chemoimmunotherapy

Prostate Cancer

Gene Expression Modulation

Toll-Like Receptor Activation

IKK Inhibitors

Oncoprotein Kinase

Mitogen Activated Protein Kinase

54 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12458659 - Methods for treating macrophage-mediated diseases, and methods of identifying agents useful therefore (2025-11-04),

2. 12458630 - Combination therapy for cancer (2025-11-04),

3. 11958901 - Anti-CXCR5 antibodies and compositions and uses thereof (2024-04-16),

4. 11617761 - Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor (2023-04-04),

5. 11065280 - Hepatocytes with high regenerative capacity for liver repair (2021-07-20),

6. 10875915 - Anti-CXCR5 antibodies and compositions and uses thereof (2020-12-29),

7. 10869880 - Methods for treating NLRP3 inflammasome-associated diseases, and methods of identifying agents useful therefor (2020-12-22),

8. 10722523 - Chemoimmunotherapy for epithelial cancer (2020-07-28),

9. 10034462 - Animal model of nash-induced hepatocellular carcinoma and methods for developing specific therapeutics (2018-07-31),

10. 9565840 - Fibrotic non-human animal, and use thereof (2017-02-14),

11. 9433686 - Methods for treating castration resistant prostate cancer and metastasis by reducing B-cell number and/or function (2016-09-06),

12. 8227193 - Compositions and methods for gene expression (2012-07-24),

13. 7776527 - Methods and compositions for reducing microbial induced apoptosis (2010-08-17),

14. 7695921 - Method for detecting the presence of prostate cancer (2010-04-13),

15. 7588912 - Compositions and methods for preventing and treating anthrax diseases (2009-09-15),

Title: The Innovative Journey of Michael Karin

Introduction: Michael Karin is a renowned inventor based in La Jolla, California. His groundbreaking work in the field of inventions has significantly impacted various industries.

Latest Patents: Michael Karin holds several patents related to biotechnology and medical devices, showcasing his continuous commitment to innovation.

Career Highlights: With a career spanning over three decades, Michael Karin has been instrumental in developing cutting-edge technologies that have revolutionized the way we approach healthcare and biotechnology.

Collaborations: Throughout his career, Michael Karin has collaborated with leading research institutions, universities, and companies to bring his inventions to life, further solidifying his reputation as a visionary inventor.

Conclusion: Michael Karin's dedication to innovation and his passion for creating impactful inventions have cemented his legacy as a pioneering figure in the world of technology and biotechnology.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

8 patents pending:

Please report any incorrect information to support@idiyas.com

1 patent pending (CIPO):

Please report any incorrect information to support@idiyas.com

2 patents pending (EPO):

Please report any incorrect information to support@idiyas.com